RT Journal Article
SR Electronic
T1 Modeling of aerosol transmission of airborne pathogens in ICU rooms of COVID-19 patients with acute respiratory failure
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.11.20247551
DO 10.1101/2020.12.11.20247551
A1 Crawford, Cyril
A1 Vanoli, Emmanuel
A1 Decorde, Baptiste
A1 Lancelot, Maxime
A1 Duprat, Camille
A1 Josserand, Christophe
A1 Jilesen, Jonathan
A1 Bouadma, Lila
A1 Timsit, Jean-François
YR 2021
UL http://medrxiv.org/content/early/2021/06/07/2020.12.11.20247551.abstract
AB The COVID-19 pandemic has generated many concerns about cross-contamination risks, particularly in hospital settings and Intensive Care Units (ICU). Virus-laden aerosols produced by infected patients can propagate throughout ventilated rooms and put medical personnel entering them at risk. Experimental results found with a schlieren optical method have shown that the air flows generated by a cough and normal breathing were modified by the oxygenation technique used, especially when using High Flow Nasal Canulae, increasing the shedding of potentially infectious airborne particles. This study also uses a 3D Computational Fluid Dynamics model based on a Lattice Boltzmann Method to simulate the air flows as well as the movement of numerous airborne particles produced by a patient’s cough within an ICU room under negative pressure. The effects of different mitigation scenarii on the amount of aerosols potentially containing SARS-CoV-2 that are extracted through the ventilation system are investigated. Numerical results indicate that adequate bed orientation and additional air treatment unit positioning can increase by 40% the number of particles extracted and decrease by 25% the amount of particles deposited on surfaces 45s after shedding. This approach could help lay the grounds for a more comprehensive way to tackle contamination risks in hospitals, as the model can be seen as a proof of concept and be adapted to any room configuration.Competing Interest StatementJean-Francois Timsit: - For the submitted work: None to declare. - Outside the submitted work: advisory board participations (Merck, Pfizer, Bayer, Nabriva, Paratek, BD); lectures (Merck, Pfizer, Biomerieux); grants to research unit (Merck, Pfizer, 3M).Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB : Comite de Protection des Personnes (CCP Ile de France XI) IDRCB number : 2020-001457-43 Ref. CPP : 20037-25957 Ethical approval was givenAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data used for analysis are available and have been deposited at Zenodo. https://doi.org/10.5281/zenodo.4056819